BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase (human recombinant)) by argenx is neonatal fc receptor blockers [moa]. Approved for endoglycosidase [epc]. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYVGART HYTRULO is an injectable biologic combining efgartigimod alfa (neonatal Fc receptor blocker) with hyaluronidase to enable subcutaneous administration for myasthenia gravis. It blocks the neonatal Fc receptor to reduce pathogenic autoantibody levels in patients with generalized MG. The product represents a formulation innovation over the intravenous VYVGART, expanding access and convenience.
$9MPart D
GrowthGrowing
Early-stage growth product with modest current penetration; commercial teams should expect scaling of field and market access functions over 24–36 months.
Mechanism of Action
Neonatal Fc Receptor Blockers
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
Started Jan 2026
25 enrolled
Myasthenia Gravis Generalized
Career Relevance
Working on VYVGART HYTRULO places you in a niche but strategically important product targeting rare autoimmune disease with growing market recognition. This is an ideal role for Commercial leaders seeking to build expertise in specialty/rare disease go-to-market strategy and establish a track record scaling a recently approved injectable biologic.
Director
Worked on VYVGART HYTRULO at argenx? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.